# Radotinib

Source: https://onco.cc/drugs/radotinib/  
OnCo record `radotinib` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Radotinib is an oral kinase inhibitor from Il-Yang Pharm. Co., Ltd., in registered phase 3 trials for chronic myeloid leukaemia.

## Summary

Radotinib is listed on ClinicalTrials.gov as an intervention in 1 registered phase 3 trial sponsored by Il-Yang Pharm. Co., Ltd., in chronic myeloid leukaemia. A kinase inhibitor: the name stem -tinib marks a small molecule that blocks a tyrosine kinase driving tumour growth. The registry record does not state which kinase unless named in the trial entries below. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-09-16
- Also known as: Supect
- Tags: pipeline; ctgov-ingest; registry-only
- Modality: Oral kinase inhibitor
- Mechanism: A kinase inhibitor: the name stem -tinib marks a small molecule that blocks a tyrosine kinase driving tumour growth. The registry record does not state which kinase unless named in the trial entries below.

## Sources

- ClinicalTrials.gov: trials of Radotinib: https://clinicaltrials.gov/search?intr=Radotinib

## Connected records

- cancers: [Chronic myeloid leukaemia (CML)](https://onco.cc/cancers/cml/)
- trials: [Randomized Evaluation of Radotinib Versus Imatinib in Phase III Study for Efficacy With Chinese Patients (RERISE China)](https://onco.cc/trials/nct03722420/)

---
JSON: https://onco.cc/api/v1/entities/radotinib.json